Company / Operating Cash Flow
Tvardi Therapeutics, Inc. Operating Cash Flow History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$78.7M
FY2024
5-year range
-$109.2M / -$5.5M
FY2020-FY2024
Trend
-31.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$109M in FY2021 to $3M in FY2015.
Based on SEC 10-K filings.
-$79M in FY2024.
Declined from -$5M to -$79M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating cash flow decreased 31.0% year-over-year.
- Peak operating cash flow was recorded in FY2015.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$78.7M | -31.0% |
| FY2023 | -$60.1M | -995.1% |
| FY2022 | -$5.5M | +95.0% |
| FY2021 | -$109.2M | -389.8% |
| FY2020 | -$22.3M | +59.3% |
| FY2019 | -$54.8M | -15.7% |
| FY2018 | -$47.4M | -120.6% |
| FY2017 | -$21.5M | -21.7% |
| FY2016 | -$17.6M | -723.6% |
| FY2015 | $2.8M | +146.9% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026